The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia : Lessons from the NOPHO ALL-92 and ALL-2000 protocols. / Taskinen, Mervi; Oskarsson, Trausti; Levinsen, Mette; Bottai, Matteo; Hellebostad, Marit; Jonsson, Olafur Gisli; Lähteenmäki, Päivi; Schmiegelow, Kjeld; Heyman, Mats.

I: Pediatric Blood & Cancer, Bind 64, Nr. 2, 02.2017, s. 242-249.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Taskinen, M, Oskarsson, T, Levinsen, M, Bottai, M, Hellebostad, M, Jonsson, OG, Lähteenmäki, P, Schmiegelow, K & Heyman, M 2017, 'The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols', Pediatric Blood & Cancer, bind 64, nr. 2, s. 242-249. https://doi.org/10.1002/pbc.26191

APA

Taskinen, M., Oskarsson, T., Levinsen, M., Bottai, M., Hellebostad, M., Jonsson, O. G., ... Heyman, M. (2017). The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols. Pediatric Blood & Cancer, 64(2), 242-249. https://doi.org/10.1002/pbc.26191

Vancouver

Taskinen M, Oskarsson T, Levinsen M, Bottai M, Hellebostad M, Jonsson OG o.a. The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols. Pediatric Blood & Cancer. 2017 feb;64(2):242-249. https://doi.org/10.1002/pbc.26191

Author

Taskinen, Mervi ; Oskarsson, Trausti ; Levinsen, Mette ; Bottai, Matteo ; Hellebostad, Marit ; Jonsson, Olafur Gisli ; Lähteenmäki, Päivi ; Schmiegelow, Kjeld ; Heyman, Mats. / The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia : Lessons from the NOPHO ALL-92 and ALL-2000 protocols. I: Pediatric Blood & Cancer. 2017 ; Bind 64, Nr. 2. s. 242-249.

Bibtex

@article{8f736089ff154669b85ee5365558a3b2,
title = "The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia: Lessons from the NOPHO ALL-92 and ALL-2000 protocols",
abstract = "BACKGROUND: Central nervous system irradiation (CNS-RT) has played a central role in the cure of acute lymphoblastic leukemia (ALL), but due to the risk of long-term toxicity, it is now considered a less-favorable method of CNS-directed therapy.PROCEDURES: Retrospectively, we estimated the effect of CNS involvement and CNS-RT on events and overall survival (OS) in 835 children treated for high-risk ALL in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000 trials.RESULTS: We did not observe a statistically significant difference in the OS or event-free survival (EFS) in patients with CNS involvement at diagnosis, but the risk of isolated CNS relapse was higher (hazard ratio [HR] 7.09, P < 0.001). CNS-RT was given to 169 of the 783 patients in first complete remission, of which 16 had CNS involvement at diagnosis. In general, CNS-RT improved EFS (HR 0.58, P < 0.05) but not OS (HR 0.69, P = n.s.). The adjusted HRs for all relapses, isolated bone marrow relapse, CNS-involving relapse, and isolated CNS relapse, were 0.47 (P < 0.01), 0.50 (P < 0.05), 0.34 (P < 0.01), and 0.12 (P < 0.01), respectively, in irradiated patients.CONCLUSIONS: CNS-RT was associated with an advantage in EFS by decreasing the risk of relapse but without improving OS.",
keywords = "Adolescent, Central Nervous System Neoplasms/etiology, Child, Child, Preschool, Combined Modality Therapy, Cranial Irradiation, Female, Follow-Up Studies, Humans, Infant, Male, Neoplasm Recurrence, Local/etiology, Neoplasm Staging, Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications, Prognosis, Retrospective Studies, Survival Rate",
author = "Mervi Taskinen and Trausti Oskarsson and Mette Levinsen and Matteo Bottai and Marit Hellebostad and Jonsson, {Olafur Gisli} and P{\"a}ivi L{\"a}hteenm{\"a}ki and Kjeld Schmiegelow and Mats Heyman",
note = "{\circledC} 2016 Wiley Periodicals, Inc.",
year = "2017",
month = "2",
doi = "10.1002/pbc.26191",
language = "English",
volume = "64",
pages = "242--249",
journal = "Pediatric Blood & Cancer",
issn = "1545-5009",
publisher = "JohnWiley & Sons, Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - The effect of central nervous system involvement and irradiation in childhood acute lymphoblastic leukemia

T2 - Lessons from the NOPHO ALL-92 and ALL-2000 protocols

AU - Taskinen, Mervi

AU - Oskarsson, Trausti

AU - Levinsen, Mette

AU - Bottai, Matteo

AU - Hellebostad, Marit

AU - Jonsson, Olafur Gisli

AU - Lähteenmäki, Päivi

AU - Schmiegelow, Kjeld

AU - Heyman, Mats

N1 - © 2016 Wiley Periodicals, Inc.

PY - 2017/2

Y1 - 2017/2

N2 - BACKGROUND: Central nervous system irradiation (CNS-RT) has played a central role in the cure of acute lymphoblastic leukemia (ALL), but due to the risk of long-term toxicity, it is now considered a less-favorable method of CNS-directed therapy.PROCEDURES: Retrospectively, we estimated the effect of CNS involvement and CNS-RT on events and overall survival (OS) in 835 children treated for high-risk ALL in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000 trials.RESULTS: We did not observe a statistically significant difference in the OS or event-free survival (EFS) in patients with CNS involvement at diagnosis, but the risk of isolated CNS relapse was higher (hazard ratio [HR] 7.09, P < 0.001). CNS-RT was given to 169 of the 783 patients in first complete remission, of which 16 had CNS involvement at diagnosis. In general, CNS-RT improved EFS (HR 0.58, P < 0.05) but not OS (HR 0.69, P = n.s.). The adjusted HRs for all relapses, isolated bone marrow relapse, CNS-involving relapse, and isolated CNS relapse, were 0.47 (P < 0.01), 0.50 (P < 0.05), 0.34 (P < 0.01), and 0.12 (P < 0.01), respectively, in irradiated patients.CONCLUSIONS: CNS-RT was associated with an advantage in EFS by decreasing the risk of relapse but without improving OS.

AB - BACKGROUND: Central nervous system irradiation (CNS-RT) has played a central role in the cure of acute lymphoblastic leukemia (ALL), but due to the risk of long-term toxicity, it is now considered a less-favorable method of CNS-directed therapy.PROCEDURES: Retrospectively, we estimated the effect of CNS involvement and CNS-RT on events and overall survival (OS) in 835 children treated for high-risk ALL in the Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000 trials.RESULTS: We did not observe a statistically significant difference in the OS or event-free survival (EFS) in patients with CNS involvement at diagnosis, but the risk of isolated CNS relapse was higher (hazard ratio [HR] 7.09, P < 0.001). CNS-RT was given to 169 of the 783 patients in first complete remission, of which 16 had CNS involvement at diagnosis. In general, CNS-RT improved EFS (HR 0.58, P < 0.05) but not OS (HR 0.69, P = n.s.). The adjusted HRs for all relapses, isolated bone marrow relapse, CNS-involving relapse, and isolated CNS relapse, were 0.47 (P < 0.01), 0.50 (P < 0.05), 0.34 (P < 0.01), and 0.12 (P < 0.01), respectively, in irradiated patients.CONCLUSIONS: CNS-RT was associated with an advantage in EFS by decreasing the risk of relapse but without improving OS.

KW - Adolescent

KW - Central Nervous System Neoplasms/etiology

KW - Child

KW - Child, Preschool

KW - Combined Modality Therapy

KW - Cranial Irradiation

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Infant

KW - Male

KW - Neoplasm Recurrence, Local/etiology

KW - Neoplasm Staging

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications

KW - Prognosis

KW - Retrospective Studies

KW - Survival Rate

U2 - 10.1002/pbc.26191

DO - 10.1002/pbc.26191

M3 - Journal article

C2 - 27748030

VL - 64

SP - 242

EP - 249

JO - Pediatric Blood & Cancer

JF - Pediatric Blood & Cancer

SN - 1545-5009

IS - 2

ER -

ID: 195153992